 
  
  
 
 
A Prospective, Multicenter, Single Arm Clinical Study Evaluatin g the Use  of 
J-Plasma® for Dermal Resurfacing  
 
Clinical Study Protocol  
   
Study P rotocol N o:  VP-1558  
 
Revision No.:         2 
 
Version Date:              November 5, 2018 
 
Sponsor:   Bovie Medical Corporation 
                                                                             5115 Ulmerton Road 
                                                                             Clearwater, FL  33760 -4004 USA  
                                                                             Phone:  (800)  537- 2790  
                                                                             Fax:  (800)  323- 1640  
 
 
 
 
 
 
 
 
 
 
Confidentiality Statement: 
This protocol, its contents, and the information relating to it are the proprietary property of Bovie 
Medical Corporation. All information is to be kept confidential.
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 2 of 36 
  
Table of Contents  
 
1 STUDY SYNOPSIS  ....................................................................................................5  
2 STUDY ADMINISTRATIVE  STRUCTURE  .............................................................6  
3 INTRODUCTION  .......................................................................................................7  
3.1 Study Background .............................................................................................................. 7 
3.2 Study Rationale  ................................................................................................................... 8 
3.3 Study Device Description  ................................................................................................... 8 
4 STUDY DESIGN .......................................................................................................10  
4.1 Study Objective  ................................................................................................................ 10 
4.2 Study Design ..................................................................................................................... 10 
4.3 Study Endpoints  ................................................................................................................ 10 
4.3.1  Primary Efficacy Endpoint  ........................................................................................... 10 
4.3.2  Primary Safety Variable  ............................................................................................... 10 
4.3.3  Secondary Efficacy Endpoint  ....................................................................................... 10 
4.3.4  Secondary Safety Variable ........................................................................................... 11 
4.3.5  Additional Endpoints  .................................................................................................... 11 
4.3.6  Subgroup Analysis  ....................................................................................................... 11 
5 INVESTIGATORS SELECT ION AND STUDY POPULATION  ...........................12  
5.1 Investigator Selection  ....................................................................................................... 12 
5.2 Study Population  ............................................................................................................... 12 
5.2.1  Inclusion Criteria  .......................................................................................................... 12 
5.2.2  Exclusion Criteria  ......................................................................................................... 13 
6 STUDY PROCEDURES  ...........................................................................................14  
6.1 Informed Consent  ............................................................................................................. 14 
6.2 Pre-Procedure  ................................................................................................................... 14 
6.3 Study Procedure  ................................................................................................................ 14 
6.4 Follow -up Procedures  ....................................................................................................... 15 
6.5 Data Collection  ................................................................................................................. 16 
6.6 Confidentiality of Data  ..................................................................................................... 17 
7 EVALUATION TOOLS  ............................................................................................17  
7.1 Fitzpatrick Skin Scale (FSS)  ............................................................................................. 17 
7.2 Fitzpatrick Wrinkle and Elastosis Scale (FWS)  ............................................................... 17 
7.3 Modified Global Aesthetic Improvement Scale (GAIS)  .................................................. 18 
7.4 Re-epithelization and Down Time  .................................................................................... 19 
7.5 Visual Analog Scale (VAS)  .............................................................................................. 19 
7.6 Subject Diary  .................................................................................................................... 19 
7.7 Blinded Identification of 3- Month Images  ....................................................................... 20 
8 ADVERSE EVENTS ASSES SMENT REPORTING  ...............................................21  
8.1 Adverse Events Evaluation  ............................................................................................... 21 
8.2 Adverse Event (AE) Definition  ........................................................................................ 21 
8.3 Serious Adverse Event (SAE) Definition  ......................................................................... 21 
8.4 Unanticipated Adverse Device Effect (UADEs) Definition  ............................................. 22 
8.5 Reporting Requirements  ................................................................................................... 22 
8.6 Severity of Adverse Events  .............................................................................................. 22 
8.7 Relationship to the Study Device and/or Procedure  ......................................................... 22 
9 RISK AND BENEFITS  .............................................................................................23  
9.1 Benefits  ............................................................................................................................. 23 
9.2 Risks  ................................................................................................................................. 23 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 3 of 36 
 9.3 Mitigation of Risks  ........................................................................................................... 24 
10 STUDY MANAGEMENT/COM PLIANCE/ QUALITY ASSURANCE .............25  
10.1  Protocol Deviation Reporting ........................................................................................... 25 
10.2  Discontinuatio n of Study Subjects .................................................................................... 25 
10.3  Supply of Study Materials  ................................................................................................ 25 
10.4  Device Malfunction/Observations  .................................................................................... 25 
10.5  Monitoring  ........................................................................................................................ 25 
10.6  End of Study  ..................................................................................................................... 26 
10.6.1  Premature Termination or Suspension of the Study or a Study Site  ................... 26 
10.7  Audits / Inspections  .......................................................................................................... 26 
11 STATISTICAL METHODOL OGY  ......................................................................27  
11.1  Determination of Sample Size  .......................................................................................... 27 
11.2  Analysis Sets ..................................................................................................................... 27 
11.2.1  Full Analysis Set (FAS)  ....................................................................................... 27 
11.2.2  Per Protocol Set (PPS)  ......................................................................................... 27 
11.3  Endpoints for Analysis  ..................................................................................................... 28 
11.3.1  Primary Efficacy Endpoint  ......................................................................... 28 
11.3.2  Secondary Efficacy Endpoint  ..................................................................... 28 
11.4  Statistical Analysis for Safety Variables  .......................................................................... 28 
11.4.1  Primary Safety Variable  .............................................................................. 28 
11.4.2  Secondary Safety Variables ........................................................................ 28 
11.5  Additional Endpoints  ........................................................................................................ 28 
11.6  Statistical Analysis for Efficacy and Additional Endpoints  ............................................. 29 
11.7  Subgroup Analysis  ............................................................................................................ 30 
11.8  Other Statistical/Analytical Issues  .................................................................................... 30 
11.8.1  Discontinuations and Missing Data  ............................................................ 30 
12 DATA HANDLING AND RE CORDKEEPING  ..................................................32  
12.1  Investigat or Records  ......................................................................................................... 32 
12.2  Investigator Reports  .......................................................................................................... 32 
12.3  Data Management Responsibilities  .................................................................................. 33 
12.4  Data Capture Methods  ...................................................................................................... 34 
13 PUBLICATION POLICY  .....................................................................................34  
14 REFERENCES  ......................................................................................................35  
 APPENDICES …………………… …….…………………………………………………… 33  
   
List of Tables  
 
Table 1: Study Required Procedures  ......................................................................................... 16 
Table 2: Fitzpatrick Skin Scale Evaluation  ............................................................................... 17 
Table 3: Fitzpatrick Wrinkle and Elastosis Scale  ...................................................................... 18 
Table 4 a: Modified Global Aesthetic Improvement Scale Evaluation (GAIS): Investigator  .... 18 
Table 4 b: Modified Global Aesthetic Improvement Scale  Evaluation (GAIS): Subject  ........... 18 
Table 5: Required Investigator Reports  ..................................................................................... 32 
 
List of Appendices  
 Appendix A:  Sample Case Report Forms  
 Appendix B:  Sample Informed Consent Form  
 Appendix C:  Subject Diary 
 
 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 4 of 36 
   
LIST OF ABBREVIATIONS  
 
AE Adverse Event  
CRF  Case Report Form  
CRO  Clinical Research Organization  
DCF  Data Clarification Form  
DRM  Data Review Meeting  
ESU  Electrosurgical Generator Unit  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
FSS Fitzpatrick Skin Scale  
FWS  Fitzpatrick Wrinkle and Elastosis Scale  
GAIS  Global Aesthetic Improvement Scale  
GCP  Good Clinical Practice  
ICH  International Conference for Harmonization of Technical Requirements of 
Pharmaceuticals for Human Use  
IFU Instructions for Use  
IPR Independent Photographic Reviewer  
IRB Institutional Review Board  
ITT Intent -to-Treat  
NSAID  Non-steroidal Anti -Inflammatory Drug  
PP Per Protocol  
PSR Plasma Skin Resurfacing  
PPS Per Protocol Set  
RF Radiofrequency  
SAE  Serious Adverse Event  
UADE  Unanticipated Adverse D evice Effect 
VAS  Visual Analog Scale  
 
  
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 5 of 36 
 1 STUDY SYNOPSIS  
Study T itle A Prospective, Multicenter, Single -Arm Clinical Study Evaluati ng the Use  of J-
Plasma® for Dermal Resurfacing  
Study Device  J-Plasma® system  
Study 
Population  The study population will consist of males and females, 30 years of age  or older , 
requesting a procedure for the purpose of improving facial appearance by reducing 
facial wrinkles and rhytides . Those subject s who meet eligibility criteria and agree 
to provide written informed consent will be invited to participate.  
Study 
Objective  The study objective is to demonstrate the safety and efficacy of the J-Plasma® 
system for use in dermal skin resurfacing.  
Study Design  
 This is a multi -center, single arm, evaluator -blind prospective study of 55 s tudy 
subject s who are seeking  a procedure to reduce the appearance of  wrinkles and 
rhytides from up to 5 investigational centers  in the United States . Each study 
subject  will receive one procedure with J-Plasma® at enrollment. Foll ow-up will 
occur immediately following the  procedure, at 1 0 days, 1, 3, and 6 months after 
enrollment.  
Study 
Endpoint s 
 Primary Efficacy E ndpoint  is the comparison of the proportion of subject s (i.e. 
percentage of treatment responders) with a ≥ 1- score improvement on the FWS at 
the 3- month visit, as compared to baseline as determined by at least 2 out of 3 
blinded Independent Photographic Reviewers.  The study design assumes a 75% success rate of subjects with treated wrinkles with a ≥ 1 -score change on the FWS; 
therefore, greater than 75% of subject s must be rated with a ≥ 1- score 
improvement 3 months after treatment and must be statistically significantly 
greater than 75%. 
 
Primary Safety V ariable  is the evaluation of adverse events up to the 3- month 
visit after treatment.  
 
Secondary Efficacy Endpoint :  
Subjects with a ≥ 1- score improvement on the FWS and at least a self -reported 
“improved” rating on the modified GAIS at the 3 -month visit will be c onsidered to 
have an aesthetic pleasing outcome. The modified GAIS is a measure of aesthetic 
improvement r elative to the baseline, pre -treatment condition.  
 
Secondary Safety V ariable  is the evaluation of the pain and discomfort after 
treatment as reported by the subject  on a visual analog scale (VAS).  
Additional  
Endpoints  • FWS ≥ 1 -score  improvement and ≥ 75% agreement with at least an 
“improved” rating by the subject  on the modified GAIS.  
• Magnitude of improvement measured by the mean change in FWS from 
baseline to 3 months visit.  
• Subject  satisfaction with procedure recorded at the 3 -month visit.  
• Achievement of  re-epithelialization  by facial zone and across all facial zones 
at the 10 day , 1-month and 3- month follow -up visit s as reported by the 
investigator . 
• Mean duration until study subject  feels comfortable going in public after 
treatment as reported by the study subject .  
• Daily 10-point Visual Analog Scale (VAS) pain assessment follo wing 
treatment through the 10 day follow -up visit by diary day with a change from 
the VAS pain score at baseline . 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 6 of 36 
 • The proportion of subjects (i.e. percentage of treatment responders) with 
correctly identified 3 -month image s, in comparison to baseline, as determined 
by at least 2 out of 3 blinded Independent Photographic Reviewers.  
 
Planned Study 
Period  Study enrollment is expected to occur over 3-6 months. Imaging and study 
assessments will continue through 3 months post -procedure, with long term subject  
follow -up and data collection through 6 months post -procedure. Total study 
duration is expected to be approximately 9 -12 months.  It is expected th at the 
510(k)  application for the device will be submitted based on 3 month post -
procedure results. However, this clinical trial will continue until every enrolled 
subject  has reached 6 months following their procedure.  At that time, the trial will 
be considered complete, the final results will be determined, and a final report will 
be prepared.  
2 STUDY ADMINISTRATIVE  STRUCTURE  
 
Study Sponsor:                     Bovie Medical Corporation 5115 Ulmerton Road Clearwater, FL  33760 -4004  
Phone:  (800)537- 2790  
Fax:  (800)323- 1640  
Clinical R esearch  
Organization (CRO):   NAMSA 400 Hwy 169 South, STE 500 Minneapolis, MN 55426 
  
Proprietary Notice:  This document contains mainly unpublished data and is the sole property of the Sponsor. Therefore, it is provided to y ou in strict 
confidence as an investigator, potential investigator, or consultant. The information may be reviewed by you, your staff, and your institutional review board. It is understood that this information will not be disclosed to others without written authorization from the study Sponsor except to the extent necessary to obtain informed consent from those persons to whom the investigational device may be implanted.  
 
Ethics Statement:  The study will be completed in accordance with applicable 
regulatio ns and standards to provide public assurance that the 
rights, safety, and well -being of stud y subject s are protected, 
consistent with the principles that have their origin in the 
Declaration of Helsinki.  
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 7 of 36 
 3 INTRODUCTION 
3.1 Study B ackground  
Physiologic al skin aging is multi factorial and result s from both intrinsic and extrinsic factors.  
Genetics  is one example of an i ntrinsic factor , others include hormone and metabolic processes 
that can cause the skin to age.  Exposure to chronic light , radiation, pollution, chemicals and 
toxins , are examples of extrinsic factors . Since skin health and beauty is contemplated as one of 
the representation of overall “well -being” and “health”, several anti -aging therapies have been 
developed during the recent  years. The goal of  these therapies is to achieve a healthy, smooth, 
blemish -free, translucent and resilient skin . [1] 
Skin resurfacing or peel procedures have become an established non- surgical method for 
reducing certain skin imperfections such as wrinkles, rhytides, dark spots, scars, or blemishes.  
Traditional fully ablative and fractional lasers are the most commonly used devices for skin resurfacing.  
The skin is composed of three layers:  the epidermis, the dermis, and the hypodermis.  The dermis contains well- organized and oriented collagen fibers that contribute to the firmness and 
smoothness of the skin.  As people age, these collagen fibers reduce in number and become less organized, resulting in sagging and/or wrinkled skin. When esthetic procedures are scheduled  
for older adults , the rate of the epidermal turnover  associated with a slower wound healing and 
less effective desquamation  (shading of outer layers of the skin) , needs to be taken into 
consideration.
[1]  
In most skin resurfacing procedures, an energy source  (heat, radiofrequency energy, etc.) is used 
to selectively damage the skin and prompt a healing response that stimulates the growth of new collagen fibers in the dermis that are well- organized.  The healing response and new collagen 
formation results in s kin that is smoother and firmer.   
There are numerous traditional fully ablative and fractional lasers on the market today used for skin resurfacing.  Traditional and fractional lasers differ in their method of treatment.  Traditional lasers have a single beam that burns or damages all of the epidermis within t he 
treatment area of the beam. Fractional lasers divide the beam into multiple smaller beams and treat only a “fraction” of the epidermis to affect changes in the deeper epidermis or dermis. This results in multiple small cores of laser damage surrounded by areas of healthy tissue.  When 
compared to traditional lasers, fractional lasers deliver a more superficial treatment resulting in less risk for complications and reduced time for healing. However, this also means more 
treatments may be required to achieve the desired results especially in areas of deep lines or wrinkles.  Healing times  vary by amount of treatment, but fractional laser recovery time is 
typically one week compared to three to four wee ks for traditional laser s. 
In the wake of the demonstrated safety and efficacy of laser skin resurfacing, multiple additional treatment modalities have been developed for this application including the use of radiofrequency (RF) energy . The fractionated radiofrequency results in epidermal and 
subepidermal ablation under the conductive pins that reproduces similar effects as a fractional 
CO 2 laser with dermal heating, seen in the non- ablative lasers and devices.[2] The combination 
of epiderma l ablation and dermal heating with radiofrequency, called sublative resurfacing in 
some studies, is suitable for skin types I –IV, for the treatment of skin laxity, wrinkles, enlarged 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 8 of 36 
 pores, pigmented lesions, acne, telangiectasias, and scar ring from trauma  or acne. Subject  
recovery and down time periods are significantly lower when compared with ablative laser 
healing times, with minimal adverse effects.[3] 
3.2 Study Rationale  
An emerging method utilizing the state of matter known as plasma to create a thermal effect on 
the skin through the use of positively ionized gasses is plasma skin resurfacing (PSR).[4] As this 
plasma comes in contact with the resurfacing target, the positive ions capture back electrons 
while energy is released. With PSR, an inert  gaseous source is used to form a plasma that 
releases thermal energy that eliminates oxygen from the targeted skin surface. [5,6] PSR is not 
dependent on a chromophore for its use and does not vaporize tissue as ablative lasers do. This 
resurfacing modality has been hypothesized to function by forming a layer of desiccated epidermis creating a natural barrier that facilitates accelerated healing with generation of new epidermis. PSR also penetrates to the upper dermis resulting in thermal denaturation of surrounding collagen, thereby increasing fibroblast activity, which has been shown to continue up to a year after the plasma treatments.
 [7] Plasma resurfacing has been safely used in 
Fitzpatrick skin types I –IV. It has been approved for the treatment of many skin c onditions 
including photoaging, acne scars, rhytides, dyschromias, skin laxity, as well as the treatment of actinic keratosis and seborrheic keratosis. In contrast to the ablative laser, plasma resurfacing treatments have a very low incidence of side effects such as permanent hypopigmentation, scarring, or prolonged erythema.
 [8] 
As an alternative treatment modality  for skin resurfacing , Bovie Medical Corporation ha s 
developed the J-Plasma® system that delivers RF energy in a controlled fashion with similar 
depth of thermal effect as predicate devices currently on the market for dermal resurfacing and wrinkle reduction procedures . 
[9,10,11] A po tential  benefit of this single -treatment low-risk 
technology  is reducing  wrinkle appearance and enhancing  well-being  by improving  satisfaction 
and perception of having a more youthful appearance.  
3.3 Study Device Description  
The J -Plasma® system consists of an electrosurgical generator unit (ESU , Figure 1 ), a handpiece  
(Figure 2), and a supply of helium gas.  RF energy is delivered to the handpiece by the ESU and 
used to energize an electrode.  When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject  in the form of a precise helium plasma beam.   
 
      
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 9 of 36 
  
  
 
 
  
 
 
Bovie Medical  Corporation’s J -Plasma
® helium -based plasma technology has received FDA 
clearance (K112233, K151325, K152570, and K170188) for the cutting, coagulation, and 
ablation of soft tissue.   
Pre-clinical studies comparing J -Plasma® to other energy sources such as CO 2 laser and RF 
energy demonstrated less or comparable lateral and depth of thermal spread for J -Plasma® in 
porcine peritoneum, bladder, and small intestine[12].   
Additionally, a pre -clinical study comparing J -Plasma® to the Rhytec Portrait PSR for ablation 
of porcine dermis was conducted to evaluate performance the J -Plasma®.  Four animals were 
utilized in the study to evaluate both devices at acute and chronic time points.  At the acute time 
point, J -Plasma using 1 pass at both 20% and 40% power was very similar to the results 
observed with the Rhytec system at PSR2 and PSR3 settings.  At the chronic time p oint, dermal 
changes with the J -Plasma® appeared to extend deeper into the dermis than that observed with 
the Rhytec treated tissue, which may be beneficial and possibly demonstrate superior performance.  These results support  the safety of J -Plasma
® for this application and equivalent 
tissue effects for the two technologies .   
These p re-clinical study results demonstrate safety and efficacy of the J-Plasma® system in the 
ablation of soft tissue within its current FDA cleared indications  in an animal model , therefore 
making the  J-Plasma® system a viable technology for dermal skin resurfacing.  
   
Figure 1: Electrosurgical generator unit  
Figure 2: Handpiece  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 10 of 36 
 4 STUDY DESIGN  
4.1 Study  Objective 
The study objective is to demonstrate the safety and efficacy of the J -Plasma® system for use in 
dermal skin resurfacing .  
4.2 Study  Design  
This is a multi- center, single arm , evaluator -blind prospective study of 55 s tudy subject s who 
are seeking a procedure to reduce the appearance of wrinkle s and rhytides at up to 5 
investigational centers  in the United States . 
 
Study subject s that meet  study eligibility  criteria and have provided informed consent will be 
enrolled in the study . During t he procedure , the investigators will use J -Plasma® on applicable  
facial zones to reduce wrinkles and rhytides.   
Study subject s will be followed immediatel y following the procedure, at 1 0 days, 1, 3, and 6 
months post -procedure  for study assessments.  
Study enrollment is expected to occur over 3- 6 months . Imaging and study assessments will 
continue through 6  months post -procedure. Total study duration is expected to be approximately 
9-12 months.  It is expected that the 510(k)  application for the device will be submitted based 
on 3 month post -procedure results. However, this clinical trial will continue until every enrolled 
subject  has reached 6 months follow ing their procedure.  At that time, the trial will be 
considered complete, the final results will be determined, and a final report will be prepared.  
4.3 Study E ndpoints  
The following endpoints will be assessed in this study .  
4.3.1  Primary Efficacy Endpoint  
The primary efficacy endpoint is the comparison of the proportion of subject s (i.e. 
percentage of treatment responders) with a ≥ 1 -score  improvement on the FWS at the 3-
month visit, as compared to baseline  as determined by at least 2 out of 3 blinded 
Indep endent Photographic Reviewers .  The study design assumes a 75% success rate of 
subjects with treated wrinkles with a ≥ 1 -score change on the FWS; therefore, greater 
than 75% of subject s  m u s t  b e  r a t e d  w i t h  a  ≥  1 -score improvement 3 months after 
treatment an d must be statistically significantly greater than 75%.  
4.3.2  Primary Safety Variable  
The primary safety variable is the evaluation of adverse events up to the 3- month visit 
after treatment.  
4.3.3  Secondary Efficacy Endpoint  
Subjects with a ≥ 1 -score improvement on the FWS and at least a self -reported 
“improved” rating on the modified GAIS at the 3 -month visit will be considered to have 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 11 of 36 
 an aesthetic pleasing outcome. The modified GAIS is a measure of aesthetic 
improvement relative to the baseline, pre- treatment condition .   
 
4.3.4  Secondary Safety V ariable  
The secondary safety variable is the evaluation of the pain and discomfort after 
treatment as reported by the subject  on a visual analog scale (VAS).  
4.3.5  Additional E ndpoints  
Other endpoints to be evaluated include:  
 1. F W S  ≥  1 -score improvement and ≥ 75% agreement with at least an “improved” 
rating by the subject  on the modified GAIS. The modified GAIS is a measure of 
aesthetic improvement relative to the baseline, pre -treatment condition.  
2. Magnitude of improvement measured by the mean c hange in FWS from baseline to 
3 months  visit.  
3. Subject  satisfaction with procedure recorded at the 3- month visit.  
4. Achievement of  re-epithelialization  by facial zone and across all facial zones  at the 
10 day , 1-month and 3- month follow -up visit s as reported by the investigator . 
5. Mean duration until study subject  feels comfortable going in public after treatment 
as reported by the study subject . 
6. Daily 10- point Visual Analog Scale (VAS) pain  assessment following treatment 
through the 10 day follow -up visit by diary day with a change from the VAS pain 
score at baseline.  
7. The proportion of subjects (i.e. percentage of treatment responders) with correct identification of 3 -month images, in compar ison to baseline, as determined by at 
least 2 out of 3 blinded Independent Photographic Reviewers.  
 
4.3.6  Subgroup Analysis  
Subgroup analyses will include stratifying the primary endpoint, (percent treatment responders on FWS ), on age, gender, race/ethnicity, and Fitzpatrick Skin Scale (FSS).  
Additionally, the degree of improvement on FWS (e.g. 2, 3 or 4- score improvement) 
will be reported.  
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 12 of 36 
 5 INVESTIGATORS SELECT ION AND STUDY POPULATION  
5.1 Investigator Selection   
Participating Investigators will b e qualified based on professionals experienced in treatment of 
wrinkles, such as dermatologists or plastic surgeons.  Investigators will be selected based on 
interest and availability for participation in  the study ; ability to provide qualified subject s; 
adequate support staff ; experience conducting clinical research ; and willingness to comply with 
the protocol, IRB requirements, regulatory requirements (including the signed investigator agreement and statements disclosing any financial relationship inves tigators might have with 
Bovie Medical Corporation), and FDA regulations . 
5.2 Study Population   
All subject s requesting a procedure for the purpose of improving  facial appearance by reducing 
facial wrinkles  and rhytides  from each participating investigator’s subject  population will be 
considered as candidates for the study.  Those subject s who meet eligibility  criteria and a gree to 
provide written informed consent  will be invited to participate.   
Subject s will be considered enrolled i nto the study when they ha ve signed an approved 
informed consent form , meet all study criteria, and have undergone a procedure  with the J -
Plasma system.  
5.2.1  Inclusion  Criteria  
     Potential subject s must meet all of the following inclusion criteria:  
 
1. Male or female subject s ≥30 years  of age .  
2. Subject  is seeking improvement of facial appearance by reducing facial wrinkles  and 
rhytides.  
3. Subject  with a facial wrinkle score rating of at least 2  on the  FWS  as determined by 
the investigator . 
4. Subject  with a Fitzpatrick Skin Scale score ≤ III. 
5. Subject  is willing and able to p rovide written informed consent.  
6. Subject  is willing and able to comply with protocol requirements, including 
obtaining study -required images /photos  and assessments, and returning for follow -
up visits.  
7. Subject  is wi lling to release rights to study Sponsor  for the use of the photos, 
including in potential publication. 
8. Subject  is willing to abstain from other facial cosmetic procedures through the 6 
month follow -up visit; examples include, but are not limited to, laser or chemical re -
surfacing, dermabrasion, neuromodulator  and/or filler  injections, aesthetic facial 
surgery , etc.  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 13 of 36 
 5.2.2  Exclusion C riteria  
     Subject s will be excluded from the study if  they meet any of the following criteria:  
 
1. Subject  with a Fitzpatrick Skin Scale score > III. 
2. Subject  is pregnant or lactating.  
3. Active HSV -1 or diabetes mellitus.  
4. Active cut, wound, or infection on the skin of the face.  
5. Subject  has used, within the past 30 days, Accutane or any medication that can cause 
dermal hypersensitivity.  
6. Subject  has a history of autoimmune disease. 
7. Subject with a bleeding disorder or who is on blood thinning medication that may be 
at risk for bleeding.  
8. Subject  has a known adverse reaction to anesthetics . 
9. Subject s with active skin disease of the facial area or known connective tissue 
disease.  
10. Subject s with known susceptibility to keloid formation or hypertrophic scarring.  
11. Subject s with present cancerous or  pre-cancerous lesions in the area to be treated.  
12. Subject  who, for any reason, suspects that they will not be able to complete the 
prescribed follow -up assessment(s);  
13. Subject  has had concurrent therapy that, in the investigator’s opinion, would 
interfere with the evaluation of the safety and efficacy of the study treatment method. 
14. Subject  is not willing to release rights to study Sponsor for the use of the photos, 
including in potential publication. 
15. Subject  is enrolled in another investi gational (drug or device) clinical trial that can 
interfere with this study ’s assessments.  
16. Subject  has undergone a facelift procedure  or received facial injections  within the 
past year.
 
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 14 of 36 
 6 STUDY PROCEDURES  
6.1 Informed Consent  
The Investigator must ensure that written informed consent to participate in the study and 
written authorization for use and disclosure of protected health information i s obtained before 
inclu ding any individual as a subject  in the study, and before conducting any study -related 
assessments. The Investigator must  provide the prospective subject  with sufficient opportunity 
to consider whether or not to participate, and minimize the possibility of coercion or undue 
influence.  
 
To participate in the study, a subject  must sign and date an IRB -approved consent document.  
The original, signed documents will be kept with the subject s’ files and copies will be provided 
to the subject s. The informed consent process must be followed, and the subject’s participation 
in the study, must be documented in the subject’s medical  record/chart.  
6.2 Pre-Procedure  
The subject s will have verification of eligibility criteria,  a brief general examin ation including 
medical history, and wrinkles/rhytides as sessment  completed within 21 day s prior to undergoing 
the study procedure. Up to t wo urine preg nancy test s must be obtained prior to study procedure 
for females with child -bearing potential  (one at pre-procedure screening and one on the day of 
the procedure  prior to the procedure  if pre -procedure screening and procedure are not performed 
on the same day ).  
Additionally, photographs of the area to be treated with the study device will be taken using the 
Canfield Scientific Visia -CR 2.3 system (see al so Section 12.3 Data Management 
Responsibilities and Section 12.3 Data Capture Methods ) for each subject  to document the 
appearance of their facial wrinkles and rhytides. The same standardized photography views will be used throughout the study a s document ed in the Canfield User Manual  document  developed 
for the study . 
The study subject s may be given medication for the prophylactic treatment of bacterial and viral 
infections including herpes simplex based on investigator’s discretion.  
 Medications subject  is taking  upon entry into the study should also be documented in the C ase 
Report Forms (CRF ). Documentation should include medications that study subject s take on an 
elective basis  in addition to prescribed medications . Medication used for analgesia and/or 
anesthesia should be recorded as concomitant medication as well. To ensure the capture of the 
foregoing  information on pre -existing conditions, sites should also be attentive to the need to  
document without limitation and whenever discover ed: (1) all chronic, episodic or ‘as  needed’ 
medications used before study enrollment; (2) prior episodic or ‘as needed’  therapeutic 
interventions, procedures or hospitalizations; and, (3) recent or planned surgical procedures.   
6.3 Study P rocedure  
On the day of the procedure and prior to  the study procedure, female subjects  with child -bearing 
potential  must complete a urine pregnancy test (result must be obtained prior to the procedure).  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 15 of 36 
 Additionally, subjects must complete a VAS pain assessment pre -procedure and immediately 
following the procedure.   
During the study procedure, the fac e of each subject  will be treated by the study investigator 
using J -Plasma® according to the IFU  and procedures described in this section . The face will be 
divided into 5 zones:  Zone 1 (perioral), Zone 2 (periorbital), Zone 3 (forehead), Zone 4 (nose), 
and Zone 5 (cheeks).  Tumescent (a n anesthetic ) will be injected under the subject ’s skin .  The  
volume of tumescent used in each Zone will  be based on  the investigator’s discretion  and will 
be documented in the CRF s. The plasma beam will be used to ablate the tissue in each Zone  
using slow , but steady movement of the beam. All Zones  will be treated with only a single pass  
of the plasma beam . Special care must  be taken to not pass over any treated area more than 
once.   Zone 1 (perioral) and Zone 2 (periorbital) will be treated with a maximum of 20% power 
and 4 liters/minute helium flow.  Z ones 3, 4, and 5 (forehead, nose, and cheeks, respectively)  
will be treated with a maximum of 40%  power and 4 liters/minute of helium flow.  The ablated 
tissue  will not be wiped away.    
6.4 Follow -up Procedures  
Following the procedure, the research staff and the subject  will care for the treated areas using  
the Post -Procedure  Care Guidelines  listed below: 
 
Post-Procedure Care Guidelines  
Days 0- 10: 
• Keep skin moist at all times, us e of a cool mist vaporizer on face as much as possible  
is recommended  
• Keep skin covered with a generous layer of petroleum jelly (i.e., Vaseline Petroleum 
Jelly) at all times  
• Perform cool water soaks every 1 -2 hours as tolerated on days 0- 2, then every 2 -4 
hours  on days 3- 10 
 Fill a clean bowl with cold tap water and a few ice cubes and 1 tablespoon of 
white vinegar for every cup of water  
 Using clean 4x4 gauze pads, wet  them with the water solution and apply over 
the face, replacing them with new wet gauzes before they dry ; alternatively, 
cold water  may be  repeatedly  dripped over the gauze 
 Continue soak for approximately 30 minutes  
• After soak is over, pat dry with a clean, soft towel and reapply petroleum jelly  
Days 11 and beyond:  
• Apply l ight moisturizer and sun protection as directed by the investigator  
 
   
Following the study procedure, subject s will be asked to complete VAS pain assessment and 
return to the study site at 1 0 days  (9-14 days) , 1 month (23-37 days) , 3 months  (80-100 days) , 
and 6 months  (166- 194 days)  for post-procedure assessments and to complete questionnaires  or 
answer questions asked by study staff .  Additionally, photographs of the treated areas  will be 
taken using the Canfield Scientific Visia -CR 2.3 system (see also Section 12.3 Data 
Management Responsibilities and Section 12.3 Data Capture Methods) for each subject to 
document the appearance of their facial wrinkles and rhytides .  Study subject s will also  be asked 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 16 of 36 
 to report complications experienced post -procedure  and complete daily VAS  0-10 scale pain 
assessments utilizing the Subject Diary (see Appendix C: Subject Diary) , and date when study 
subject  felt comfortable, willing and able to go in p ublic following the procedure . Table 1 
illustrates study procedures that will occur at each visit.  
 
Table 1:  Study Required Procedures  
 
 Baseline / 
Pre-
Procedure 
Screening1 Procedure 10 Days  1 mo  3 mo  6 mo  
10+4/-1 
days 30±7 
days 90±10 
days 180±14 
days 
Informed Consent  √      
Assess Inclusion/Exclusion Criteria  √      
Urine Pregnancy Test2 √ √     
Medical History  √      
General Physical Exam  √      
Review Medications  √  √ √ √ √ 
Photographic Images3 √  √ √ √ √ 
Fitzpatrick Skin Scale (FSS)  √      
Fitzpatrick Wrinkle and Elastosis 
Scale (FWS) 4 √  √ √ √ √ 
Visual Analog Scale ( 10-point 
VAS) 5  √ √ √ √ √ 
Study Procedure   √     
Subject Diary (10-point VAS )6  √ √    
Adverse Event Assessment   √ √ √ √ √ 
Re-epithelization and Down Time7   √ √ √  
Modified Global Aesthetic 
Improvement Scale (GAIS) 8    √ √ √ √ 
1 Pre-procedure Screening  assessments to take place within 21 days prior to undergoing the procedure.  
2 Up to two urine pregnancy tests must be obtained prior to study procedure for females with child -bearing potential 
(one at pre -procedure screening and one on the day of the procedure prior to the procedure if screening and 
procedure are not performed on th e same day). 
3Digital photographs of the subject ’s face will be taken and labeled according to Photography Instructions.  
4To be completed by Investigator and Independent Photographic Reviewers (IPRs).  
5 To be completed by the study subject  on a day of the procedure (prior to the procedure and immediately following 
the procedure) and at all follow -up visits .  
6 To be completed by the study subject daily starting from the day of procedure (after procedure, at home ) until the 
10 day  follow -up visit.   
7 To be completed by  Investigator  and/or Independent Photographic Reviewer  (as applicable)  to capture 
achievement of  epidermal recovery  status at follow -up visit s; and date when study subject  felt comfortable, willing 
and able to go in public following study proce dure (assessed at the 10 day follow -up visit) .  
8 To be completed by Investigator and study subject  at all study follow -up visits.  
6.5 Data Collection  
Subject  demographic information, procedural data, adverse events, device observations , and 
study required assessments will be documented on the CRFs.  Study subject s will complete 
Visual Analog Scale and Modified Global Aest hetic Improvement Scale (GAIS): Subject  Form  
at follow -up visits . 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 17 of 36 
 6.6 Confidentiality of Data  
The Principal Investigator will oversee the conduct of the study and all data will be kept 
confidential. Confidentiality will be maintained by using subject  identifica tion numbers instead 
of names. Informed c onsent  forms, data collection sheets a nd records, linking a subject ’s name 
with their ID number will be  maintained in a locked cabinet or locked office. Information to be 
stored on the computer will be  identified by subject ID and will be password protected.  
 Data disclosed outside the study team will be de -identified or will only include general gr oup 
demographic information. Protected Health  Information and/or identifiable study data will not 
be shared with anyone outside the study team or  Health System, with the exception of the study 
sponsor, and federal regulators/ institutional officials  for th e purposes of auditing. 
7 EVALUATION TOOLS  
The following evaluation tools will be used in this study:  
7.1 Fitzpatrick Skin Scale (FSS)  
Assessment  of subject ’s skin color will be determined prior to study procedure  by the 
Investigator using the FSS .  The scale delineates skin color into the c ategories as shown in 
Table 2.  
 
Table 2 : Fitzpatrick Skin Scale Evaluation  
Skin Type  Description  
Type I  White skin that never tans and always burns easily  
Type II  White skin that tans slightly and always burns easily  
Type III  Light brown skin that tans gradually and can burn moderately  
Type IV  Moderately brown skin that tans well and burns slightly  
Type V  Dark brown skin that tans profusely and burns rarely  
Type VI  Black skin with deep pigmentation that never burns   
7.2 Fitzpatrick Wrinkle and Elastosis  Scale (FWS)  
Assessment of subject  wrinkles at baseline and follow -up visits will be performed by the 
Investigator and assessment of subject wrinkles at baseline and follow -up visits (excluding the 
10 day follow -up visit) will be performed by three board- certified dermatologists  or plastic 
surgeons  sourced and managed by Canfield Scientific , called Independent Photographic  
Reviewers (IPRs) , using the Fitzpatrick Wrinkle and Elastosis  Scale ( FWS ) categories as shown 
in Table 3  (see also Section 12.3 Data Management Responsibilities and Section 12.3 Data 
Capture Methods ). The FWS is a clinically validated assessment tool used to assess skin 
wrinkle severity and elastosis  on a scale from 1 through 9, where the lower score is considered 
better. Three Independent Photographic Reviewer s will be blinded to the study subject ’s visit 
(baseline and all applicable follow -up visits ) and  will perform photographic assessments of each 
subject ’s wrinkle depth in the treated zones (identified only as “Zones to Evaluate” to the IPRs) 
using  FWS  and ignoring nasolabial folds  and marionette lines  (effects of gravity) , and artifacts 
from the chin rest.  The IPRs will assign a single  FWS  score per subject at each  time point. 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 18 of 36 
 Each photograph will have a unique identification number, but they will not be arranged in any 
specific order.  
 A subject  will be considered a succ ess if at least 2 out of the 3 IPRs agree that the subject  has 
reached at least one degree of wrinkle score reduction per FWS when comparing the score obtained at the 3 month follow -up visit to the baseline wrinkle score.  
 
Table 3 : Fitzpatrick Wrinkle and Elastosis  Scale  
Class  Description  Score  Description  
I Fine wrinkles  1-3 Mild: Fine texture changes with subtly 
accentuated skin lines.  
II Fine to moderate depth wrinkles , 
Moderate number of lines  4-6 Moderate: Distinct papular elastosis 
(individual papules with yellow 
translucency under direct lighting) and 
dyschromia  
III Fine to deep wrinkles, numerous lines , with or without redundant 
skin folds  7-9 Severe: Multipapular and confluent 
elastosis (thickened, yellow and pallid) approaching or consisten t with cutis 
rhomboidalis.  
7.3 Modified Global Aesthetic Improvement Scale (GAIS)  
The Global Aesthetic Improvement Scale (GAIS) is a subjective rating of improvement in 
treatment results compared to pre -treatment.  A modification of the GAIS to include “much 
worse” and “very much worse”  as rating options  will be used in this study .  The Investigator 
will grade  the overall improvement of treatment area  as indicated in Table 4a by comparing the 
subject ’s appearance at follow -up visits against a photograph taken prior to procedure .  
Likewise, the subject  will also rate their improvement compared to pre -treatment  as shown in 
Table 4b .   
 
The modified GAIS results will be collected at all follow -up visits .   
 
Table 4a: Modified Global Aesthetic Improvement Scale Evaluation (GAIS): Investigator  
Rating  Description  
Very much 
improved  Optimal cosmetic result from this procedure in this subject  
Much improved Marked improvement in appearance from the initial condition, but not 
completely optimal for this subject  
Improved Obvious improvement in appearance from the initial condition  
No change  The appearance is essentially the same as the original condition  
Worse   The appearance is worse than the original condition  
Much worse  The appearance is much worse than the original condition  
Very much worse  The appearance is very much worse than the original condition  
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 19 of 36 
 Table 4b: Modified Global 
Aesthetic Improvement Scale 
Evaluation (GAIS): Subject  
Rating  
Very much 
improved  □ 
Much improved  □ 
Improved □ 
No change  □ 
Worse  □ 
Much worse  □ 
Very much worse  □ 
 
7.4 Re-epithelization and Down Time  
The study investigators  and/or Independent Photographic Reviewers (as applicable) will be  
require d to obtain and document re -epithelization and down time defined as per below:   
1. Achievement of Re-epithelization  - determine percentage epidermal recovery  per 
treatment zone  at all follow -up visit s. 
2. Down Time  - date when study subject  felt comfortable, willing and able to go in public 
following study procedure  (assessed at the 10 day follow -up visit) . 
7.5 Visual Analog Scale (VAS)  
The s tudy subject s will be asked to complete a 10 -point Visual Analog Scale (VAS)  for the 
following assessments: 
1. Level of pain and discomfort associated with study procedure – to be completed by the 
subject s on the day of the procedure (prior to the procedure and immediately following  
the procedure) , daily between the date of the procedure  (reported at home) and  the 10 
day follow -up visit, and at all  follow -up visits. 
2. Subject  satisfaction with treatment – at all follow -up visits. Additionally, the subject s 
will be asked if they would recommend the treatment to friends and acquaintances (yes, 
perhaps, or no)  
 
Scoring will consist of making a mark on a 10 -cm line demarcated  at 1-cm intervals. Each end 
of the line will be  awarded a score of 0 or 10 according to the extreme points of reference  
pertaining to an individual measure.  
 
7.6 Subject Diary  
Study subjects will be asked to complete a daily diary (see Appendix C: Subject Diary) starting 
from  the procedure date (after study procedure, at home ) until  the 10 day follow -up visit  to 
complete daily 10- point VAS pain assessments and document  any complications they  have  
experienced.  
 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 20 of 36 
 7.7 Blinded Identification of 3 -Month Images  
Assessment of each subject’ s baseline and 3 -month follow -up images viewed simultaneously 
will be performed by the Independent Photographic Reviewers  who will be blinded to the study 
subject ’s visit (baseline and 3- month follow -up visit ).  Each IPR will view each subj ect’s 
randomized baseline and 3- month follow -up images and assess which set of images represent 
the subject’s post -treatment images. Each photograph will have a unique identification number, 
but the sets of images will not be arranged in any specific order . 
 
A subject will be considered a success if at least 2 out of the 3 IPRs correctly identify the 3 -
month images.  
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 21 of 36 
 8 ADVERSE EVENTS ASSESSMENT  REPORTING  
8.1 Adverse Events Evaluation  
Safety evaluations for this study include an interview with the study subject  at each follow -up 
visit by the  Investigator or Research Coordinator to elicit information about any medical 
occurrence that meets the definition of Adverse Event. This  information will be  documented in 
CRF without regard for cause or relation to device and/or procedure.  
 
In addition, study subject s will be instructed to report all of complications experienced post 
study procedure to the site personnel as soon as they occur/ are observed.                                                                                                                                                      
 
It is the Investigator’ s responsibility to determine seriousness, severity, and relatedness of the 
Adverse Event to the device and procedure using the definitions below.  
8.2 Adverse E vent (AE) Definition  
An adverse event  (AE) is any untoward or unfavorable medical occurrence in a human subject , 
including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease temporally associated with the subject ’s participation in the research, 
whether or not considered related to the subject ’s participation in the research.  
 A preexisting condition ( one that is present at the start of the study ) will be recorded as an AE 
only if the frequency, inte nsity, or the character of the condition worsens during the study 
period.   Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as an AE in the following circumstances: hospitalization or prolonged hospitalization for diagnostic 
or elective surgical procedures for a preexisting condition. Surgery should not be reported as an outcome of an AE if the purpose of the surgery was elective or diagnostic and the outcome was uneventful.  
8.3 Serious Adverse Event (SAE)  Definition  
Serious Adverse Event (SAE)  is an adverse event that:  
• Led to a death or  
• Led to a serious deterioration in the health of a subject that:  
o Resulted in a life -threatening illness or injury,  
o Resulted in a permanent impairment of a body structure or body function, 
o Required in- patient  hospitalization or prolongation of existing hospitalization, 
o Resulted in medical or surgical intervention to prevent impairment to body structure or a body function, or  
o Led to fetal distress, fetal death or a congenital abnorm ality or birth defect.   
 All SAEs that occur during the study period, whether considered to be related to the investigational product or not , must be reported to the Sponsor within 24 hours of knowledge of 
the event. IRB reporting requirements may also apply for SAEs.  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 22 of 36 
 8.4 Unanticipated Adverse Device Effect  (UADEs)  Definition  
An unanticipated adverse device effect  (UADEs)  is defined as any serious adverse effect on 
health or safety or any life- threatening problem or death caused by, or associated with, a device, 
if that effect, problem, or death was not previously identified in nature, severity, or degree of 
incidence in the investigational plan, or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.   
In addition, any UADEs  will be reported to the Sponsor  and the reviewing IRB as soon as 
possible, but no later than within 24 hours of knowledge of the event.   
All adverse events, anticipated or unanticipated, will be monitored until they are adequately 
resolved or explained.    
8.5 Reporting Requirements  
All adverse events (AEs) obser ved by study subject s, investigators or other study staff from first 
exposure to the study product through last study follow -up visit will be recorded. If a devic e-
related AE, SAE, or unanticipated serious device related effect is ongoing at the final study visit, the subject  will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or the subject  is lost to follow -up. The investigator should make every 
effort to ensure that follow -up includes any supplemental investigations as may be indicated to 
elucidate, as completely as practical, the nature and/or causality of the AE or SAE. This may include unscheduled follow up visits for AE assessment.  
Study subject s will be instructed to report all AEs to the clinical study staff.  AE information 
will be collected throughout the study, and recorded on CRFs.  
8.6 Severity of Adverse E vents  
The severity of adverse events  will be ca tegorized using the following criteria:  
• Mild:  easily tolerated by the subject , causing minimal discomfort and not interfering 
with everyday activities. These events generally do not require treatment.  
• Moderate:  sufficiently discomforting to interfere with normal everyday activities.  
These vents are usually relieved by simple therapeutic measures.  
• Severe:   prevents normal, everyday activities.  These events may require systemic drug 
therapy or other medical treatment.  
8.7 Relationship to the Study D evice and /or P rocedure 
The relationship to the study device and/or  procedure will be determined by the investigator 
utilizing the following categories: 
 
• Not Related:  An event for which an alternative explanation is conclusively identified –  
e.g., concomitant drug(s), concomitant disease(s), and/or the relationship in time suggests that a causal relationship is highly  unlikely.  
 
• Related : The adverse event follows a reasonable temporal sequence related to treatment 
by the device, follows a known or suspected response pattern and a plausible alternative etiology cannot be identified. 
 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 23 of 36 
 • Undetermined : The relation of the ad verse event has some temporal relationship  to the 
device and/or device procedure , is not clearly due to another condition and the 
involvement of the study device is unknown.  
 
9 RISK AND BENEFITS  
9.1 Benefits  
A possible  benefit of usi ng J-Plasma  is the potential for improvement in wrinkle severity.   
Additional potential benefits of improving the appearance of wrinkles could include enhanced 
well-being, with improved satisfaction with the appearance of less facial wrinkles or the 
perception of a havin g a more youthful appearance.  
9.2 Risks  
Potential risks with J-Plasma  are similar to those that are encountered for many routine facial 
soft tissue reduc tions.  These include but are not limited to:  
• pain, 
• tenderness,  
• itching,  
• bleeding,  
• bruising/ hematoma/seroma,  
• allergic reaction,   
• hypersensitivity to the treatment (resulting in erythema, swelling, induration and/or 
urticaria),  
• post-inflammatory hyperpigmentation,  
• telangiectasias,  
• skin overheating/burn,  
• hypertrophic scarring  
• calcification,  
• discoloration/ permanent hypopigmentation,  
• loss of correction,  
• vessel laceration or o cclusion,  
• abscess at treatment  site which may result in induration and/or scar formation, and 
• prolonged wound healing.   
Subject s using drugs that reduce coagulation (aspirin or NSAIDs) may experience increased 
bruising or bleeding at the treatment site.  
Additionally, other wrinkle reduction  products have shown rare occurrences of the following 
symptoms:  
• systemic events such as flu -like symptoms (such as fever, headac he, myalgia, neuralgia, 
nausea, malaise or dizziness),  
• pruritis,  
• shedding,  
• flaking,  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 24 of 36 
 • scaling,  
• peeling,  
• rash,  
• transient visual disturbances (blurred vision),  
• tingling,  
• numbness,  
• transient polyarthralgia,  
• infection,   
• anaphylactic response (hypotension, difficulty breathing, tightne ss in chest, and/or 
shortness of  breath).  
 
Side effects of Tumescent anesthesia containing lidocaine or epinephrine include:  
• Nausea  
• Vomiting  
• Mild sleepiness  
 
9.3 Mitigation of Risks  
These risks are mitigated b y utilizing qualified clinical I nvestigators who have training and are 
experienced in wrinkle reduc tion procedures and following study treatment procedures .  In 
addition, risks are mitigated by including only those subject s that meet the study eligibility  
criteria.  This study also includes evaluation of study subject  satisfaction with this procedure. 
Given the anticipated acceptable risk, the risk -benefit assessment of the use of J -Plasma  for use 
in dermal skin resurfacing appears to  offer a substantial clinical benefit at  a reasonable risk.  
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 25 of 36 
 10 STUDY MANAGEMENT/COM PLIANCE/ QUALITY ASSURANCE  
10.1 Protocol Deviation Reporting 
A protocol deviation is an event in which the investigator or site personnel did not conduct the 
study in accordance w ith the protocol or the Clinical Trial Agreement.  Prior approval by the 
Sponsor  is expected in situations where the Investigator anticipates, contemplates, or makes a 
conscious decision to deviate.  Prior approval is not required when a deviation is neces sary to 
protect the life or physical well- being of a subject  in an emergency.  Prior approval is not 
expected in situations where unforeseen circumstances are beyond the  Investigator’s control 
(e.g. inadvertent errors, product  failure, or inability to perf orm required procedures due to 
subject ’s illness).   
All protocol deviations are to be reported to the Sponsor , along with the justification for the 
deviation, on the Protocol Deviation CRF.  Protocol deviations should be reported as soon as possible upon center notification of the deviation.   
10.2 Discontinuation of Study Subject s 
A subject  may discontinue  from the study at any time  without any penalty or loss of benefits to 
which the subject  is otherwise entitled. An Investigator may also discontinue  a subject  from the 
study without the subject ’s consent, if the Investigator feels it is in the best medical interest of 
the subject .  The date and the reason for study withdrawal will be indicated on the Study Exit 
CRF.  Every effort should be made to contac t subject s lost to follow -up, and all such efforts 
should be documented in the subject ’s file.  
10.3 Supply of Study Materials  
Each clinical site will be provided with the investigational devices. A Device Accountability Log will be used to track the receipt, us e and return of study devices at each study site. All 
investigational devices w ill be returned to study Sponsor  after en rollment of all subject s. Study 
Sponsor  will provide appropriate packaging and shipping instructions to the study site s. 
10.4 Device Malfunct ion/Observations  
All malfunctions of, or defects of the  delivery system will be recorded on the Device 
Malfunction/Observation Case Report F orm and reported to the S ponsor  by the investigational 
sites.  This will include situations w here the delivery system did not  perform as intende d; user 
errors; study device/component being physically defective, including out of the box failure .   
10.5 Monitoring  
It is the responsibility of the study S ponsor to ensure that proper monitoring of this clinical 
investigation is conducted.  Appropriately trained personnel appointed by the Sponsor  will 
conduct monitoring activities, as needed, and ensure that the investigation is conducted in accordance with the study protocol, the Clinical Trial Agreement, applicable laws and 
regulations , including ICH GCP , and overseeing IRBs. 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 26 of 36 
 Prior to  study initiation at each investigational site , approval to enroll subject s will be given by 
the S ponsor and/or designee .   
The Sponsor  will determine frequency and timing of interim or periodic monitoring visits for  
each site based on enrollment rate , volume, study compliance, and findings from previous visits.  
Each enrolling site  will be visited at least annually.  During a m onitoring visit, the M onitor will 
evaluate the site’s compliance with regulatory and protocol requirements, verify data recorded 
on CRFs to available source documents, etc.  
In addition, the M onitor will check whether all AEs and SAEs have been reported appropriately 
within the time periods required.  
Data Clarification Forms (DCFs) will be created for identified errors on CRFs that have been 
submitted to the S ponsor to ensure errors /omissions  are corrected.  New and previous findings 
and recommended correct ive and preventative actions, if they exist, will be communicated with 
the study staff during the visit, and will also be addressed in a final letter that will be sent to the Investigator after the visit.  
10.6 End of Study  
The end of study will be defined as completion of all study visits by all enrolled subject s. If a 
device- related AE, SAE, or unanticipated serious device -related effect is ongoing at the final 
study visit, the subject  will be followed until resolution, unt il the condition stabilizes, until the 
event is otherwise explained, or the subject  is lost to follow -up.  
Study closure visits may be conducted at all clinical sites in order to review record retention requirements, device disposition requirements, etc., with site personnel.  The Sponsor may 
choose to conduct the closure visit via telephone contact if appropriate.  
10.6.1  Premature Termination or Suspension of the Study or a Study Site  
The study or parts of the study may be prematurely terminated or suspended by the Sponsor . This discontinuation may be based on a significant number of AEs of a similar 
nature that warrant such action. Furthermore, the study may be prematurely ended if the  
regulatory authority or the IRB make a recommendation to terminate or suspend approval for the study, the study site, or the Investigator.  
 
If the study is prematurely terminated or suspended for any reason, the investigator must inform the subject s and a ssure appropriate follow -up treatment. Within the timeframes 
noted in applicable regulations, the S ponsor will promptly inform the investigators, 
study sites, the IRB, and regulator y authorities of the termination or suspension of the 
study, as appropriate  
10.7 Audits / Inspections  
The Sponsor , their designee, and the reviewing IRB may monitor  or audit the study centers. 
Likewise, r egulatory authorities may inspect Sponsor or CRO files or any study center to 
evaluate the conduct of the study. The Investigator mu st allow access to the subject  files and 
inspection of their clinical research protocol procedures when requested.    
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 27 of 36 
 11 STATISTICAL METHODOLO GY 
This section describes the statistical analyses foreseen at the time of study planning.  
 
Any deviations from planned analyses, the reasons for such deviation, and all alternative or additional statistical analyses that may be performed before database close will be summarized in the C linical S tudy R eport.  
11.1 Determination of S ample S ize 
The objective of this study is to demonstrate that study participants positively respond to the J -
Plasma
® therapy, thus the primary endpoint will be assessed via the percentage of study 
participants that demonstrated an improvement in the FWS from baseline to the 3 -month visit.   
An improve ment is clinically important when there is  ≥ 1-score change.  The p lanned sample 
size to provide sufficient power for a statistical comparison of the proportion of treatment 
responders (P)  versus a reasonable cutoff (P 0) was based on a power calculation ut ilizing the 
(one proportion) binomial exact test based on the following assumptions.  
• H0: P ≤ P 0 versus H a: P > P 0 
• Type I error rate:  α = 0.05 (one -sided ) 
• Population proportion under the null hypothesis: P 0 = 0.75 
• Population proportion under the alternative hypothesis: P = 0.90 
• Total N: 50 study participants  
 Based on the above assumptions, the study power is estimated to be approximately 88%. To account for possible missing data (up to 10% attrition), a total of 55 subject s will be enrolled.  
Other tests (i.e., a test of the mean improvement of FWS) would be expected to provide more 
power.  
 
One study investigating the effects of radiofrequency energy on the improvement of appearance 
of wrinkles and rhytides (De Novo, Newa
TM) utilized a FWS cuto ff as 75%, supporti ng this 
value  in the present sample size computation .[13] 
11.2 Analysis S ets 
The f ull analysis s et (FAS)  will be used for analysis of this  study.  
11.2.1  Full Analysis Set (FAS)  
All subject s enrolled in the study who have a FWS value at baseli ne will be included  in 
the FAS .  Subjects  with missing FWS data at the  3-month visit will be imputed as no 
change and included in the FAS population.  
11.2.2  Per Protocol Set (PPS)  
The PPS is the subset of subject s in the FAS without major protocol deviations. Major 
protocol deviations will be decided and finalized at a data review meeting (DRM) that 
will be conducted prior to database lock. The efficacy analyses will be repeated on the 
PP population if there is at least a 10% difference in the numbe r of subject s in the PP S 
and intent -to-treat ( ITT) populations. 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 28 of 36 
 11.3 Endpoints for Analysis  
11.3.1  Primary E fficacy E ndpoint  
The primary efficacy endpoint is the c omparison of the proportion of subject s (i.e. 
percentage of treatment responders) with a ≥  1-score  improvement on the FWS at the 3-
month visit, as compared to baseline  as determined by at least 2 out of 3 blinded 
Independent Photographic Reviewers .  The study design assumes a 75% success rate of  
subjects with  treated wrinkles with a ≥  1-score change on the FWS; therefore, greater 
than 75% of subject s must be rated with a ≥  1-score improvement 3 months after 
treatment and must be statistically significantly greater than 75%.  
11.3.2   Secondary E fficacy E ndpoint  
Subjects with a ≥ 1 -score improvement on the FWS and at least a self -reported 
“improved” rating on the modified GAIS at the 3 -month visit will be considered to have 
an aesthetic pleasing outcome. The modified GAIS is a measure of aesthetic 
improvement relative to the baseline, pre -treatment condi tion. 
11.4 Statistical Analysis for Safety Variables  
11.4.1  Primary Safety Variable  
The primary safety variable is the evaluation of adverse events up to the 3- month visit 
after treatment.  Adverse events reported at each scheduled study visit, as well as adverse 
event s self -reported in the Subject  Diary (see Appendix C: Subject Diary) , will be 
summarized . A descriptive analysis  including type, onset after treatment, dur ation, 
severity, and relationship to study device and/or procedure  will be provided. With the 
same descriptive methodology, the duration of adverse events will be summarized with a 
delineation from 0- 7 days, 8- 14 days, 15- 28 days, and more than 28 days.  
11.4.2  Secondary Safety Variables  
The secondary safety variable is the evaluation of the pain and discomfort a fter 
treatment  as reported by the subject  on a 10- point visual analog scale (VAS) . Results of 
the VAS on a scale of 0 (no pain) to 10 (most severe pain) and the change from baseline 
will be summarized descriptively utilizing  mean, standard deviation, minimum, 
maximum, median, and the 95% confidence interval of the mean and mean change from 
baseline.   
11.5 Additional  Endpoints  
Other  endpoints to be evaluated include:  
 
1. FWS ≥ 1 -score improvement and ≥ 75% agreement with at least an “improved” rating by 
the subject  on the modified GAIS. The modified GAIS is a measure of aesthetic 
improvement relative to the baseline, pre -treatment condition.  
2. Magnitude of improvement measured by the mean change in FWS from baseline to 3-month visit.  
3. Subject  satisfaction with procedure recorded at the 3- month visit.  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 29 of 36 
 4. Achievement of  re-epithelialization  by facial zone (and across facial zones)  at the 10 -day, 
1-month and 3- month follow -up visit s as reported by the study investigator  and/or 
Independent Photographic Reviewers  (as applicable) .  
5. Mean duration until subject  feels comfortable going in public after treatment as reported 
the study subject . 
6. Daily 10- point Visual Analog Scale (VAS) pain assessment s following treatment through 
the 10 day follow -up visit by diary day with a change from the VAS pain score at baseline.  
7.   The proportion of subjects (i.e. percentage of treatment responders) with correct 
identification of 3 -month images, in comparison t o baseline, as determined by at least 2 out 
of 3 blinded Independent Photographic Reviewers.  
11.6 Statistical A nalysis for Efficacy and A dditional  Endpoints  
 
Endpoint  Variable  Statistical analyses  
Primary efficacy 
endpoint  
 Percentage of subject s 
with a ≥ 1- score  
improvement on the 
FWS from baseline to 
3-month visit  The percentage of subject s with a ≥ 1 -score  improvement 
will be summarized as counts and percentages.  This 
percentage will be compared to the cutoff of 75% using a 
binomial exact test (one -sided) . Descriptive upper 95% 
confidence limit will be provided for the difference between treatment and cutoff rate and the associated p -
value will also be provided.  
Secondary 
efficacy 
endpoint  
 Investigator – 
Modified GAIS  
  An “improvement” on the modified GAIS by the treating 
investigator at the 3 -month visit will be classified as 
“improved,” “much improved,” or “very much improved.” 
All other ratings on the modified GAIS will be classified 
as “no improvement.” Cross -tabulation of improvement 
status of  modi fied GAIS versus 1 -score FWS response 
will then be summarized as counts and percentages.  
Primary safety 
variable  Adverse event rate  Adverse event rates (total and categorized by duration) 
will be summarized as counts and percentages.  
Stratification on type, onset after treatment,  duration, 
severity, and relationship to study device and/or 
procedure  will also be provided.  
Secondary 
safety variable  Study Subject - 
Pain/Discomfort VAS 
after treatment  Evaluation of pain and discomfort  after treatment  (and the 
change from baseline)  as reported by the subject  on a 10-
point visual analog scale (VAS). Results of the VAS on a 
scale of 0 to 10 will be summarized descriptively utilizing 
mean, standard deviation, minimum, maximum, median, 
and the 95% confidence interval of the mean  and mean 
change from baseline .   
Additional 
endpoint #1  
 Study Subject  – 
Modified GAIS  
 
 An “improvement” on the modified GAIS by the subject  
at the 3 -month visit will be classified as “improved,” 
“much improved,” or “very much improved.” All other ratings on the modified GAIS will be classified as “no 
improvement.” Cross -tabulation of improvement status of 
modified GAIS versus 1 -score FWS response will then be 
summarized as counts and percentages.  
Additional 
endpoint #2  Mean change in FWS 
from baseline to 3 -Descriptive summary statistics (number of observations, 
mean, standard deviation, minimum, maximum, median, 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 30 of 36 
  month visit  95% confidence interval of the mean) will be used for 
summarizing the change in FWS from baseline to th e 3-
month visit.  The FWS from baseline to the 3- month visit 
will also be stratified on both the treating- investigator and 
subject  modified GAIS.  
Additional 
endpoint #3  
 Study subject  
satisfaction at 3 -month 
visit Evaluation of the subject  satisfaction as  reported by the 
subject  on a visual analog scale (VAS). Results of VAS on 
a scale of 0 to 10 will be summarized descriptively 
utilizing mean, standard deviation, minimum, maximum, 
median, and the 95% confidence interval of the mean.  
Cross tabulation of s ubject  satisfaction/improvement 
versus 1 -score FWS response will be summarized as 
counts and percentages.  
Additional 
endpoint #4  
 Achieve ment of  re-
epithelialization  by 
facial zone and across 
facial zone s after 
treatment  Descriptive summary statistics (number of observations, 
mean, standard deviation, minimum, maximum, median, 
95% confidence interval of the mean) will be used for 
summarizing the achievement of  re-epithelialization  by 
facial zone  and across facial zone s at all   follow -up visit s 
through the 3 -month visit .   
Additional 
endpoint #5  
 Mean duration for 
study subject  to feel 
comfortable in public 
after treatment  Descriptive summary statistics (number of observations, 
mean, standard deviation, minimum, maximum, median, 
95% confidence interval of the mean) will be used for 
summarizing the mean duration for study subject  to feel 
comfortable after treatment.   
Additi onal 
endpoint #6  Study Subject - 
Pain/Discomfort VAS 
after treatment  through 
the 10 day follow -up 
visit Descriptive summary statistics by diary day (number of 
observations, mean, standard deviation, minimum, maximum, median, 95% confidence interval of the mean)    
and the  change from the VAS pain score at baseline will 
be provided.  
Additional 
endpoint #7  Percentage of subjects 
with correct 
identification of 3 
month image  The percentage of subjects with correct identification of 3 -
month images will be summarized as count, percentage, 
and 95% exact binomial confidence interval.  
 
11.7 Subgroup A nalysis  
Subgroup analyses will include stratifying the primary endpoint (percent treatment 
responders on FWS), on age, gender, race/ethnicity, and Fitzpatrick Skin Scale (FSS).  Additionally, the degree of improvement on FWS (e.g. 2, 3 or 4- score improvement ) 
will be reported.  
11.8 Other S tatistical/ Analytical I ssues 
11.8.1  Discontinuations and Missing D ata 
Subject s with missing 3 -month FWS data will be imputed as having no chan ge from 
baseline.  No other imputations for missing data will be employed.  Furthermore, n o 
estimation of missing data for self -reported pain within the 10 day Subject D iary will be 
imputed. 
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 31 of 36 
   
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 32 of 36 
 12 DATA HANDLING AND RE CORDKEEPING  
12.1 Investigator R ecords  
The Investigator is responsible for the preparation, review, signature, and retention of the 
records listed below:  
• signed Clinical Trial Agreement and Curriculum V itae  
• all correspondence pertaining to the investigation with other investigators, the 
reviewi ng IRB, the study Sponsor, the M onitor and FDA,  
• investigational device receipt, use and disposition records,  
• subject  case history records relating to use of the device, including Case Report F orms, 
medical records, progress notes, nurses notes, etc., 
• all signe d informed consent forms,  
• all shipping and disposition records for investigational devices and relevant 
observations relating to the device, and 
• the protocol and documentation of date and reason for any deviation from investigational plan.  
Records are subject to FDA inspection and must be retained for a period of at least two  years 
after the latter of two dates:   
1. date on which the investigation is terminated or completed, or  
2. date that the records are no longer required for purposes of supporting an 
application to the FDA to market the device.  
12.2 Investigator R eports  
The Investigator is responsible for the preparation, review, signature, and submission of the 
reports listed in Table 5.  These are also subject to the FDA inspection and the retention 
requirements described above for the Investigator ’s Records.  
 
Table 5 : Required Investigator Reports  
Report  Submit to  Description  
Unanticipated Adverse 
Device Effect (UADE)  Sponsor and IRB  The Investigator must submit to the Sponsor and reviewing IRB a report of any UADE as soon as 
possible but not less than 10 working days after 
the Investigator first learns of the effect.  
Withdrawal of IRB 
Approval  Sponsor  The Investigator must report a withdrawal of the 
reviewing IRB approval within 5 working days.  
Progress Report  Sponsor, Monitor and IRB  The Investigator must submit this report at regular intervals, but not less than once per year 
to the IRB, Sponsor and Monitor.  
Deviation from Protocol 
in Emergency  Sponsor and IRB  Deviation from the study  protocol that is  made to 
protect the life or physical well -being of a 
subject  in an emergency situation must be 
reported within 5 working days after the 
emergency occurred.  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 33 of 36 
 Deviation from Protocol 
that affect the scientific 
soundness of the study 
plan or the rights, safety 
or welfare of human 
subjects  Sponsor  Prior approval by the Sponsor is required when a 
deviation of this nature is anticipated.  
 
 
Failure to obtain 
informed consent  Sponsor and IRB  If a study device was used without obtaining informed  consent, the Investigator must notify 
the Sponsor and IRB within 5 working days of 
the use of the device.    
Final Report  Sponsor and IRB  The Investigator must submit this report to the Sponsor and IRB within 3 months after the 
termination or completion of the study, or after 
the Investigator’s participation in the study is 
complete.   
 
12.3 Data Management Responsibilities  
Data collection is th e responsibility of the study staff at the site under the supervision of the site 
Principal Investigator.  During the study, the Investigator must maintain complete and accurate 
documentation for the study.   
 Electronic Data Capture (EDC) Data management and oversight is the responsibility of North American Science Associates, Inc. (NAMSA).  Responsibilities include, but are not limited to, the following:   
• Clinical strategy and oversight  
• Clinical study operations  
• File management and study documentation 
• Site initiation visits and study close -out visits  
• Clinical quality assurance  
• Statistical support and programming  
• Data management, including database development and programming and electronic 
data capture (EDC) programming, training, and management  
 
Additionally, management and oversight of photographic imaging is the responsibility of Canfield Scientific .  Responsibilities include, but are not limited to, the following:   
• Providing photographic equipment and supplies as well as installation and traini ng at 
each investigational site  
• Project management of photographic imaging throughout the investigation  
• Preparation of the User Manual for use during the study to ensure consistent serial 
photography is achieved  
• Monitoring and quality review of incoming i mages  
• Digital image management and storage  
• Management of all independent photographic panel review activities, including sourcing and contracting independent reviewers, facilitating reviews, and transferring the data per 
an approved Data Transfer Agreement  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 34 of 36 
  
 
12.4 Data Capture Methods  
Electronic Data Capture (EDC) will be utilized in the investigation.  NAMSA is responsible for creating the EDC system as well as training all sites and Sponsor on the EDC system, hosting the database/servers, and reviewing and corr ecting the data.  
 Photographic images will be captured utilizing the Canfield Scientific Visia -CR 2.3 system  as 
specified in the Canfield User Manual for the study . 
 
13 PUBLICATION POLICY 
The publication policy will be in accordance with the Investigator A greement with each 
Principal Investigator or similar agreement.  
 
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 35 of 36 
 14 REFERENCES  
 
1. Ganceviciene R,  Liakou  A,  Theodoridis  A, Makrantonaki  E,  and Zouboulis  C. Skin anti -aging 
strategies,  Dermatoendocrinol . 2012 Jul 1; 4(3): 308– 319.  
 
2. Hruza G, Taub AF, Collier SL, Mulholland SR. Skin rejuvenation and wrinkle reduction using a 
fractional radiofrequency system. J Dr ugs Dermatol.  2009;8(3):259– 265. 
 
3. Mulholland RS, Ahn DH, Kreindel M, Paul M. Fractional Ablative Radio -Frequency Resurfacing in 
Asian and Caucasian Skin: A Novel Method for Deep Radiofrequency Fractional Skin 
Rejuvenation. Journal of Cosmetics, Dermatological Sciences and Applications.  2012; 2(3):144– 150. 
 
4. Loesch  M, Somani  A, Kingsley  MM,  Travers J, Spandau  D. Skin resurfacing procedures: new and 
emerging options . Clin Cosmet Investig Dermatol . 2014; 7: 231–241.  
5. Alster TS, Konda S. Plasma Skin Resurfacing for Regeneration of Neck, Chest, and Hands: 
Investigation of a Novel Device.  Dermatol Surg. 2007; 33(11):1315–1321.  
6.    Heinlin J, Isbary G, Stolz W, et al. Plasma applications in medicine with a s pecial focus on  
       dermatology. J Eur Acad Dermatol Venereol.  2011; 25(1):1 –11.  
 
7.    Lin MG, Yang TL, Chiang CT, et al. Evaluation of dermal thermal damage by multiphoton    
       autofluorescence and second- harmonic -generation microscopy.  J Biomed Opt.2006; 11(6):064006.  
8.   Foster KW, Moy RL, Fincher EF. Advances in pla sma skin regeneration.  J Cosmet  
      Dermatol.  2008;7(3):169–179.   
 
9. Bovie Medical Corporation Data on File.   
 
10. Chernoff WG, Slatkin e M, Zair E, Mead D. Silktouch: a new technology for skin resurfacing in 
aesthetic surgery.  J Clin Laser Med Surg.  1995;13:97- 100. 
 
11. Harris DM, Bell T, From L, Schacter D.  Facial skin resurfacing with a very short pulsed CO2 laser: 
beam characteristics and initial histological results.  In: Anderson RR, et al, eds.  Lasers in Surgery: 
Advanced Characterization, Therapeutics, and Systems VII (Proceedings of Society Photo -Optical 
Instrumentation Engineers). Bellingham, Wash: SPIE -The International Society f or Optical 
Engineering; 1996;267:211 -218. 
 
12. Pedroso J, Gutierrez M, Volker W . J-Plasma, monopolar pencil, argon beam and CO 2 laser 
electrosurgery: comparative evaluation of thermal spread in a porcine tissue model  (White Paper). 
Bovie Medical Corporation. June 2014.  
 
13. EndyMed Medical Ltd., De Novo Classification Request for NewaTM: Submission Number: 
DEN150005. January 16, 2015.  
 
 
  
J-Plasma Dermal Resurfacing Study, VP -1558, Rev. No. 2         Novembe r 5, 2018  
Confidential    Page 36 of 36 
  
 
Appendices  